| An improvement of the 2ˆ (–delta delta CT) method for quantitative real-time polymerase chain reaction data analysis X Rao, X Huang, Z Zhou, X Lin Biostatistics, bioinformatics and biomathematics 3 (3), 71, 2013 | 1977 | 2013 |
| Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia H Kantarjian, Y Oki, G Garcia-Manero, X Huang, S O'Brien, J Cortes, ... Blood 109 (1), 52-57, 2007 | 986 | 2007 |
| Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience H Kantarjian, S O'Brien, E Jabbour, G Garcia-Manero, ... Blood 119 (9), 1981-1987, 2012 | 480 | 2012 |
| Shared frailty models for recurrent events and a terminal event L Liu, RA Wolfe, X Huang Biometrics 60 (3), 747-756, 2004 | 441 | 2004 |
| Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study JA Burger, MJ Keating, WG Wierda, E Hartmann, J Hoellenriegel, ... The Lancet Oncology 15 (10), 1090-1099, 2014 | 432 | 2014 |
| DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes L Shen, H Kantarjian, Y Guo, E Lin, J Shan, X Huang, D Berry, S Ahmed, ... Journal of Clinical Oncology 28 (4), 605-613, 2009 | 429 | 2009 |
| A prognostic score for patients with lower risk myelodysplastic syndrome G Garcia-Manero, J Shan, S Faderl, J Cortes, F Ravandi, G Borthakur, ... Leukemia 22 (3), 538-543, 2008 | 418 | 2008 |
| Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy X Huang, J Cortes, H Kantarjian Cancer 118 (12), 3123-3127, 2012 | 388 | 2012 |
| Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study K Takahashi, F Wang, H Kantarjian, D Doss, K Khanna, E Thompson, ... The Lancet Oncology 18 (1), 100-111, 2017 | 371 | 2017 |
| Results of the phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia M Andreeff, KR Kelly, K Yee, S Assouline, R Strair, L Popplewell, ... Clinical Cancer Research 22 (4), 868-876, 2016 | 355 | 2016 |
| Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012 SK Plevritis, D Munoz, AW Kurian, NK Stout, O Alagoz, AM Near, SJ Lee, ... Jama 319 (2), 154-164, 2018 | 315 | 2018 |
| Collaborative modeling of the benefits and harms associated with different US breast cancer screening strategies JS Mandelblatt, NK Stout, CB Schechter, JJ Van Den Broek, DL Miglioretti, ... Annals of internal medicine 164 (4), 215-225, 2016 | 314 | 2016 |
| Evidence Summary: Collaborative Modeling of US Breast Cancer Screening Strategies JS Mandelblatt, NK Stout, CB Schechter, JJ van den Broek, DL Miglioretti, ... | 314* | |
| Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study E Jabbour, H Kantarjian, F Ravandi, D Thomas, X Huang, S Faderl, ... The Lancet Oncology 16 (15), 1547-1555, 2015 | 305 | 2015 |
| Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis NJ Short, S Zhou, C Fu, DA Berry, RB Walter, SD Freeman, CS Hourigan, ... JAMA oncology, 2020 | 277 | 2020 |
| Randomized trial of ibrutinib versus ibrutinib plus rituximab in patients with chronic lymphocytic leukemia JA Burger, M Sivina, N Jain, E Kim, T Kadia, Z Estrov, ... Blood, blood-2018-10-879429, 2018 | 256 | 2018 |
| Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single … E Jabbour, NJ Short, F Ravandi, X Huang, N Daver, CD DiNardo, ... The Lancet Haematology 5 (12), e618-e627, 2018 | 246 | 2018 |
| Detection of MRD may predict the outcome of patients with Philadelphia chromosome–positive ALL treated with tyrosine kinase inhibitors plus chemotherapy F Ravandi, JL Jorgensen, DA Thomas, S O’Brien, R Garris, S Faderl, ... Blood 122 (7), 1214-1221, 2013 | 243 | 2013 |
| Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology … RB Walter, HM Kantarjian, X Huang, SA Pierce, Z Sun, HM Gundacker, ... Journal of Clinical Oncology 28 (10), 1766-1771, 2010 | 241 | 2010 |
| Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome HM Kantarjian, S O'Brien, X Huang, G Garcia‐Manero, F Ravandi, ... Cancer 109 (6), 1133-1137, 2007 | 239 | 2007 |
